News from oncosec medical incorporated A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

May 18, 2023, 16:30 ET OncoSec Announces Closing of $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company developing intratumoral...

May 16, 2023, 13:29 ET OncoSec Announces $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company developing intratumoral...

May 16, 2023, 08:00 ET OncoSec is encouraged after FDA meeting to discuss proposed neoadjuvant melanoma clinical program

OncoSec Medical Incorporated (NASDAQ: ONCS) (the Company or OncoSec), a clinical-stage biotechnology company developing intratumoral immunotherapies...

Apr 27, 2023, 07:30 ET OncoSec Receives $3.49 Million to Strengthen its Balance Sheet After Selling its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Authority NOL Program

OncoSec Medical Incorporated (NASDAQ: ONCS) (the Company or OncoSec), a clinical-stage biotechnology company developing intratumoral immunotherapies...

Apr 11, 2023, 14:06 ET OncoSec Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company developing intratumoral...

Apr 10, 2023, 11:32 ET OncoSec Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company developing intratumoral...

Apr 03, 2023, 07:00 ET OncoSec Announces Clinical Data of the KEYNOTE-695 Trial Assessing TAVO™-EP in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Melanoma Refractory to anti-PD-1 Treatment

OncoSec Medical Incorporated (NASDAQ: ONCS) (the Company or OncoSec), a clinical-stage biotechnology company developing intratumoral immunotherapies...

Dec 05, 2022, 09:00 ET OncoSec to Present at the RHK Capital Disruptive Growth Conference on December 6, 2022

OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing intratumoral...

Nov 30, 2022, 09:15 ET OncoSec Announces Pricing of $3.5 Million Public Offering

OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing intratumoral...

Nov 15, 2022, 16:45 ET OncoSec presents encouraging early data with TAVO™-EP combined with nivolumab (Opdivo®) in neoadjuvant melanoma

OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical stage biotechnology company developing intratumoral...

Nov 11, 2022, 08:38 ET OncoSec Announces Positive Clinical Data of the KEYNOTE-695 Trial Assessing TAVO-EP in Combination with Pembrolizumab (Keytruda®) in Patients with Advanced Melanoma Refractory to anti-PD-1 Treatment

OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company developing intratumoral...

Nov 08, 2022, 13:22 ET OncoSec Announces Reverse Stock Split

OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing intratumoral...

Oct 04, 2022, 17:23 ET OncoSec Announces Pipeline Prioritization and Workforce Reduction

OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing intratumoral...

Jun 24, 2022, 08:00 ET Novel pre-clinical results regarding OncoSec's intratumoral electroporation platform were highlighted as Editor's Pick in Molecular Cancer Research

OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing intratumoral...

May 23, 2022, 08:00 ET OncoSec Receives Triple Negative Breast Cancer Foundation's Vanguard Award for Excellence in Oncology Research

OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec") today announced that it is the recipient of the 2022 Vanguard Award...

Apr 29, 2022, 08:00 ET OncoSec Appoints Dr. Robert Arch as President and Chief Executive Officer

OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing intratumoral...

Feb 22, 2022, 17:59 ET OncoSec Announces Appointment of George Chi as Chief Financial Officer

OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing intratumoral...

Dec 17, 2021, 09:09 ET OncoSec Announces Changes to its Board of Directors

OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing cytokine-based ...

Nov 02, 2021, 08:00 ET OncoSec Medical Hosting SITC Key Opinion Leader Webinar on Updated Data from the KEYNOTE-695 Study

OncoSec Medical Incorporated (NASDAQ: ONCS) will host a conference call and webcast for investors and analysts on Friday, November 12 at 7:00 AM ET...

Oct 20, 2021, 16:02 ET OncoSec Provides Business Update

OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing cytokine-based ...

Aug 16, 2021, 16:01 ET OncoSec Provides Leadership Update

OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced the establishment of a Leadership Committee consisting of...

Jul 26, 2021, 08:30 ET OncoSec to Participate in Fireside Chat at BTIG Virtual Biotechnology Conference

OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced that Interim CEO and Chief Operating Officer, Brian Leuthner, ...

Jul 06, 2021, 16:01 ET OncoSec Enters into a Collaboration Agreement with Merck for a Pivotal Global Phase 3 Study, KEYNOTE-C87, of TAVO™ Combined with KEYTRUDA® for Late-Stage Metastatic Melanoma

OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced it has entered into a Clinical Trial Collaboration and Supply ...

Jun 24, 2021, 16:30 ET OncoSec Appoints Brian Leuthner as Interim Chief Executive Officer

OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced that Daniel O'Connor has resigned and that Brian Leuthner,...

Jun 14, 2021, 08:30 ET OncoSec Appoints Industry Leading Electroporation Device Expert, Jeffrey Silverman, as Vice President of Product Engineering

OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), today announced the appointment of Jeffrey Silverman as Vice President of...